# Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction

> **NCT04884243** · PHASE2 · COMPLETED · sponsor: **Cloudbreak Therapeutics, LLC** · enrollment: 92 (actual)

## Conditions studied

- Meibomian Gland Dysfunction

## Interventions

- **DRUG:** CBT-006

## Key facts

- **NCT ID:** NCT04884243
- **Lead sponsor:** Cloudbreak Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-05
- **Primary completion:** 2023-08-17
- **Final completion:** 2023-08-17
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04884243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04884243, "Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04884243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*